Invivyd Inc. Cash Flow Conversion Efficiency
Invivyd Inc. cash flow conversion efficiency. Based on the latest financial reports, Invivyd Inc. (IVVD) has a cash flow conversion efficiency ratio of -0.237x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.01 Million) by net assets ($181.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Invivyd Inc. (2020–2025)
Cash flow conversion efficiency of Invivyd Inc. from 2020 to 2025. This chart illustrates how Invivyd Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View IVVD stock price for real-time trading data and today's change.
Invivyd Inc. Cash Flow Conversion Ratio Explained
Invivyd Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Invivyd Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Invivyd Inc. ranked by their cash flow conversion efficiency. Also see market cap of Invivyd Inc. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Takkt AG
XETRA:TTK
|
0.016x |
|
QINGCI GAMES INC. -00001
F:Z56
|
N/A |
|
Intercure
TA:INCR
|
0.006x |
|
Agilyx AS
OL:AGLX
|
-0.077x |
|
Kung Sing Engineering Corp
TW:5521
|
0.279x |
|
Hostelworld Group PLC
IR:HSW
|
0.075x |
|
Ta Chia Yung Ho Machine Industry Co Ltd
TWO:2221
|
0.040x |
|
Galan Lithium Limited
F:9CH
|
-0.003x |
Annual Cash Flow Conversion Efficiency for Invivyd Inc. (2020–2025)
The table below shows the annual cash flow conversion efficiency of Invivyd Inc. from 2020 to 2025. Review Invivyd Inc. (IVVD) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $241.54 Million | $-58.13 Million | -0.241x | +90.47% |
| 2024-12-31 | $67.54 Million | $-170.49 Million | -2.524x | -158.71% |
| 2023-12-31 | $177.47 Million | $-173.16 Million | -0.976x | -57.89% |
| 2022-12-31 | $355.97 Million | $-219.99 Million | -0.618x | -86.67% |
| 2021-12-31 | $558.02 Million | $-184.74 Million | -0.331x | -248.25% |
| 2020-12-31 | $-65.25 Million | $-14.57 Million | 0.223x | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more